Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas (Q37038356)

17 August 2017

1 reference

title

Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas (English)

1 reference

17 August 2017

4

Vernon K Sondak

1 reference

17 August 2017

Audrey C Shor

1

1 reference

17 August 2017

Samuel V Agresta

series ordinal

2

1 reference

17 August 2017

Gina Z D'Amato

series ordinal

3

1 reference

17 August 2017

1 January 2008

1 reference

17 August 2017

1 reference

17 August 2017

15

1 reference

17 August 2017

1

1 reference

17 August 2017

47-54

1 reference

Sarcomas in adolescents and young adults

17 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

National survival trends of young adults with sarcoma: lack of progress is associated with lack of clinical trial participation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

National cancer clinical trials: children have equal access; adolescents do not.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

21 January 2018

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

Mechanisms of sarcoma development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

Tyrosine kinase inhibitors as cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

Biology of gastrointestinal stromal tumors: KIT mutations and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

Gastrointestinal stromal tumor (GIST) -- single center experience of prolonged treatment with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

Gastrointestinal stromal tumor (GIST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

Imatinib-induced regression of AIDS-related Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

Taking aim at Ewing's sarcoma: is KIT a target and will imatinib work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of C

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

Targeting angiogenesis for the treatment of sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

The epidermal growth factor receptor HER2 is not a major therapeutic target in Ewing sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

Herceptin down-regulates HER-2/neu and vascular endothelial growth factor expression and enhances taxol-induced cytotoxicity of human Ewing's sarcoma cells in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

Cancer targets in the Ras pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500106

10.1177/107327480801500106

21 January 2018

Identifiers

DOI

0 references

1 reference